IN2014DN00185A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00185A
IN2014DN00185A IN185DEN2014A IN2014DN00185A IN 2014DN00185 A IN2014DN00185 A IN 2014DN00185A IN 185DEN2014 A IN185DEN2014 A IN 185DEN2014A IN 2014DN00185 A IN2014DN00185 A IN 2014DN00185A
Authority
IN
India
Prior art keywords
formula
alzheimer
salt
compound represented
diagnostic agent
Prior art date
Application number
Inventor
Yuki Okumura
Yoshifumi MAYA
Yoshinari SHOYAMA
Takako Onishi
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of IN2014DN00185A publication Critical patent/IN2014DN00185A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A compound represented by formula (1) (In the formula, R1 represents a radioactive halogen substituent, and while 0-2 of A1, A2, A3 and A4 represent N , the remainder represent CH.) or a salt thereof, and an Alzheimer's diagnostic agent obtained by incorporating the compound represented by formula (1) or a salt thereof. This compound and this Alzheimer's diagnostic agent enter the brain following administration, and exhibit favorable clustering properties toward amyloid deposited in the brain.
IN185DEN2014 2011-06-24 2012-05-29 IN2014DN00185A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011140069 2011-06-24
PCT/JP2012/063726 WO2012176587A1 (en) 2011-06-24 2012-05-29 Novel compound with amyloid affinity

Publications (1)

Publication Number Publication Date
IN2014DN00185A true IN2014DN00185A (en) 2015-07-10

Family

ID=47422429

Family Applications (1)

Application Number Title Priority Date Filing Date
IN185DEN2014 IN2014DN00185A (en) 2011-06-24 2012-05-29

Country Status (11)

Country Link
US (1) US9211350B2 (en)
EP (1) EP2725027B1 (en)
JP (1) JP5167436B2 (en)
KR (1) KR101854228B1 (en)
CN (1) CN103596950B (en)
AU (1) AU2012274639B2 (en)
CA (1) CA2839199C (en)
ES (1) ES2619830T3 (en)
IN (1) IN2014DN00185A (en)
TW (1) TWI554511B (en)
WO (1) WO2012176587A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6754353B2 (en) * 2014-08-29 2020-09-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド Huntington protein imaging probe
US20200276338A1 (en) * 2017-09-19 2020-09-03 The Governors Of The University Of Alberta Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer
JP6831802B2 (en) * 2018-01-12 2021-02-17 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． Radionuclide-labeled compound and imaging agent containing it
WO2022244680A1 (en) * 2021-05-18 2022-11-24 国立大学法人大阪大学 Magnetic nanoparticles for image diagnosis and contrast medium for image diagnosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010614A1 (en) 1998-08-20 2000-03-02 Regents Of The University Of California METHODS FOR LABELING β-AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES
EP1334091B1 (en) 2000-08-24 2012-09-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease
ATE349446T1 (en) 2001-04-23 2007-01-15 Univ Pennsylvania AMYLOID PLAQUE AGGREGATION INHIBITORS AND DIAGNOSTIC IMAGING AGENTS
CN1299777C (en) 2001-08-27 2007-02-14 宾夕法尼亚州大学理事会 Stilbene derivatives and their use for binding and imaging amyloid plaques
WO2007033080A2 (en) * 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
JP4738419B2 (en) 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 Diagnostic and therapeutic agents for diseases caused by amyloid aggregation and / or deposition
RU2008150377A (en) 2006-05-19 2010-06-27 Нихон Меди-Физикс Ко., Лтд. (Jp) A NEW AMYLOID COMPOSITION
AU2007261985B2 (en) * 2006-06-21 2012-04-19 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
AU2007326707A1 (en) 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
MX2009007487A (en) * 2007-01-22 2009-08-31 Astrazeneca Ab Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives.
CA2703649A1 (en) 2007-10-24 2009-04-30 Shigeyuki Tanifuji Novel compound having affinity for amyloid
EP2213671A4 (en) 2007-10-26 2012-02-22 Nihon Mediphysics Co Ltd NEW CONNECTION WITH AFFINITY TO AMYLOID
JPWO2009057575A1 (en) 2007-10-30 2011-03-10 日本メジフィジックス株式会社 Use and production methods of novel amyloid affinity compounds
CN101909657A (en) 2007-10-30 2010-12-08 日本医事物理股份有限公司 Use of novel compound having affinity for amyloid, and process for production of the same
TW200922629A (en) 2007-10-30 2009-06-01 Nihon Mediphysics Co Ltd Utilization of novel compounds with amyloid affinity and method of producing the same
CA2725934A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted indoles
EP2218464A1 (en) * 2009-02-11 2010-08-18 Technische Universität München Compounds for non-invasive measurement of aggregates of amyloid peptides
WO2010128595A1 (en) 2009-05-07 2010-11-11 富士フイルムＲｉファーマ株式会社 Method for producing radioactive iodine-labeled imidazopyridine derivative
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CN103534253B (en) * 2011-05-20 2016-02-24 日本医事物理股份有限公司 Amyloid is had to the compound of affinity

Also Published As

Publication number Publication date
JPWO2012176587A1 (en) 2015-02-23
TWI554511B (en) 2016-10-21
KR20140040735A (en) 2014-04-03
KR101854228B1 (en) 2018-05-03
EP2725027B1 (en) 2017-03-01
CN103596950B (en) 2017-12-19
AU2012274639B2 (en) 2016-08-11
AU2012274639A1 (en) 2014-02-06
US20140121377A1 (en) 2014-05-01
ES2619830T3 (en) 2017-06-27
CA2839199C (en) 2018-11-06
TW201300388A (en) 2013-01-01
CN103596950A (en) 2014-02-19
EP2725027A1 (en) 2014-04-30
EP2725027A4 (en) 2015-02-25
WO2012176587A1 (en) 2012-12-27
US9211350B2 (en) 2015-12-15
CA2839199A1 (en) 2012-12-27
JP5167436B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
MX2020013099A (en) Heteroaromatic compounds and their use as dopamine d1 ligands.
MX2015012006A (en) Tetracyclic bromodomain inhibitors.
WO2014152389A8 (en) Imaging agent for detection of diseased cells
MX2014012695A (en) Isoindolone derivatives.
JO3702B1 (en) New gadolinium chelate compounds for use in magnetic resonance imaging
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
MX2020003112A (en) Biguanide compositions and methods of treating metabolic disorders.
HK1209109A1 (en) Pyridinone and pyridazinone derivatives
MX2014002014A (en) Formulations, use thereof as or to produce dishwashing detergents, and production thereof.
IN2012DN06602A (en)
MX2016007128A (en) Ccr6 compounds.
MX2016007440A (en) Bromodomain inhibitors.
MX2017003470A (en) Macrocyclic lrrk2 kinase inhibitors.
WO2013040227A3 (en) Therapeutic compounds
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
IN2014DN00185A (en)
PH12015501146A1 (en) Hydantoin derivative
IN2014DN09826A (en)
IN2015DN00209A (en)
PH12015501056A1 (en) 2-pyridone compound
EA201690908A1 (en) Pyrazolopyrmidine compounds
PH12014500212A1 (en) Pyrrolidine-3-ylacetic acid derivative
WO2013111013A3 (en) Methods for treating alzheimer's disease by administering certain synthetic compounds
IN2012DN06600A (en)